Top 5 Drug Type | Count |
---|---|
siRNA | 29 |
Small molecule drug | 2 |
Chemical drugs | 2 |
Target |
Mechanism APOC3 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A1AT inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ANGPTL3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date21 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Plozasiran ( APOC3 ) | Hypertriglyceridemia More | Phase 3 |
Fazirsiran ( A1AT ) | Alpha 1-Antitrypsin Deficiency More | Phase 3 |
Olpasiran ( Lp(a) ) | Atherosclerosis More | Phase 3 |
ARO-ENaC ( ENaCα x αvβ6 ) | Cystic Fibrosis More | Phase 2 |
Daplusiran/Tomligisiran ( cccDNA ) | Hepatitis B More | Phase 2 |